Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma

Kim, Dong Eon; Lee, Yonghyun; Kim, Mingyo; Lee, So‐Young; Jon, Sangyong; Lee, Seung‐Hyo

doi:10.1016/j.biomaterials.2017.06.014

Cited by 102 publications

(74 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, both intravenous and intraperitoneal application of these bilirubin nanoparticles led to the sustained elevation of serum bilirubin concentrations comparable to those typical for GS. 73 Interestingly, anticancer activities were demonstrated also for tumor tissue-targeted biotinylated bilirubin nanoparticles, again conjugated with doxorubicin in another experimental study. 74 In another study, nanoencapsulated bilirubin copolymer was shown to have antioxidant effects with increasing pancreatic islet viability as well as functional properties 75 suggesting wide therapeutic options in this newly evolving field.…”

Section: Direct Administration Of Bilirubin and Related Tetrapyrrolesmentioning

confidence: 95%

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

Vı́tek

Bellarosa

Tiribelli

2019

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. In mammals, bilirubin plays a major role as a potent antioxidant. Uridine 5’‐diphospho‐glucuronosyl transferase (UGT)1A1 variants coding for bilirubin UDP‐glucuronosyl transferase resulting in mild hyperbilirubinemia (as in Gilbert syndrome (GS)) may confer a strong genetic advantage. Strategies to boost bioavailability of bilirubin or to mimic GS represent an attractive approach to prevent many oxidative stress and inflammation‐mediated diseases. Even a tiny, micromolar increase in serum bilirubin concentrations substantially decreases the risk of oxidative stress–mediated diseases. There are several possible ways to achieve this, including lifestyle changes, changes in dietary patterns, regular physical activities, or use of chemical drug or of specific plant products either in the form of regular food items or nutraceuticals. Further basic and experimental research is required to fully uncover this promising therapeutic field.

show abstract

Section: Direct Administration Of Bilirubin and Related Tetrapyrrolesmentioning

confidence: 95%

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

Vı́tek

Bellarosa

Tiribelli

2019

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…However, clinical applications of bilirubin have been restricted due to its poor water-solubility and toxicity. To overcome the drawbacks of natural bilirubin, Jon and coworkers developed polyethylene glycol (PEG)-conjugated bilirubin nanoparticles through a combined covalent conjugation and self-assembly method, which were defined as BRNPs (Lee et al, 2016a;Kim D. E. et al, 2017;. Compared to pristine bilirubin, BRNPs have more excellent water dispersibility, better pharmacokinetic properties, and higher accumulation in oxidative stress-induced inflammatory lesions.…”

Section: Bilirubin-derived Nanoparticlesmentioning

confidence: 99%

“…Compared to pristine bilirubin, BRNPs have more excellent water dispersibility, better pharmacokinetic properties, and higher accumulation in oxidative stress-induced inflammatory lesions. More importantly, BRNPs inherited the intrinsic powerful antioxidant capability of bilirubin, as evidenced by their efficacies in the treatment of a variety of oxidative stress-associated diseases, such as hepatic ischemia-reperfusion injury , asthma (Kim D. E. et al, 2017), IBD (Lee et al, 2016a), and pancreatic islet xenotransplantation (Kim M. J. et al, 2017). In addition, BRNPs protected different cells against cytotoxicity caused by H 2 O 2 and decreased inflammatory responses resulting from activated macrophages.…”

Section: Bilirubin-derived Nanoparticlesmentioning

confidence: 99%

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Chen

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are essential in regulating various physiological functions. However, overproduction of ROS is implicated in the pathogenesis of various inflammatory diseases. Antioxidant therapy has thus represented an effective strategy for the treatment of oxidative stress relevant inflammatory diseases. Conventional anti-oxidative agents showed limited in vivo effects owing to their non-specific distribution and low retention in disease sites. Over the past decades, significant achievements have been made in the development of antioxidant nanotherapies that exhibit multiple advantages such as excellent pharmacokinetics, stable anti-oxidative activity, and intrinsic ROS-scavenging properties. This review provides a comprehensive overview on recent advances in antioxidant nanotherapies, including ROS-scavenging inorganic nanoparticles, organic nanoparticles with intrinsic antioxidant activity, and drug-loaded anti-oxidant nanoparticles. We highlight the biomedical applications of antioxidant nanotherapies in the treatment of different inflammatory diseases, with an emphasis on inflammatory bowel disease, cardiovascular disease, and brain diseases. Current challenges and future perspectives to promote clinical translation of antioxidant nanotherapies are also briefly discussed.

show abstract

“…[56] The BRNPs we synthesized have potent antioxidant, anti-inflammatory, and anti-apoptotic properties, so we investigated their protective effects against IRI in mice. [61] In cancer therapeutics, it would be ideal that the a drug delivery carrier 1) is made of biocompatible and nontoxic materials, 2) is able to release its payload in response to internal or exter-nal stimuli, 3) is easy to manufacture in a large scale and inexpensive way, and 4) per se has anticancer activity. In particular, BRNP pretreatment of mice with hepatic IRI prevented hepatocellular injury by reducing oxidative stress, the production of proinflammatory cytokines, and neutrophil recruitment.…”

Section: Bilirubinmentioning

confidence: 99%

“…Reproduced with permission. [61] Copyright 2017, Elsevier Ltd. B) Effects of different pretreatments on the renal expression of mRNAs for four cell adhesion proteins (Sele, Ccl2, Vcam1, and Icam1) after chemical induction of IRI.…”

Section: Perspective and Future Outlookmentioning

confidence: 99%

Naturally Occurring Bioactive Compound‐Derived Nanoparticles for Biomedical Applications

Saw

Lee

Jon

2019

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

Bioactive, small molecular compounds from a variety of plants and organisms have tremendous potential for use as treatments for cancer, microbial infections, inflammatory diseases, and other medical conditions. There have also been attempts to use naturally occurring bioactive compounds as delivery carriers. Such bioactive, natural compound-derived nanocarriers are expected to have better biocompatibility than synthetic material-derived drug-delivery systems and also exhibit intrinsic therapeutic efficacy. Despite these expectations, however, research on the topic is limited and thus has been the subject of very few reviews. Here, the authors describe carriers derived from four typical naturally occurring bioactive compounds-curcumin, resveratrol, epigallocatechin gallate (EGCG) (an active ingredient in green tea), and bilirubin-that have been used for biomedical applications. In this review, the pros and cons of each bioactive small molecular compound and processes for synthesizing and preparing these compound-derived delivery carriers are discussed. A number of examples that show the potential of these delivery carriers as disease treatments are considered, and their future prospects for biomedical applications are assessed. Nanoparticles that simply encapsulate or encase such bioactive compounds are outside the scope of this review and thus are not considered.

show abstract

Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma

Cited by 102 publications

References 27 publications

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Naturally Occurring Bioactive Compound‐Derived Nanoparticles for Biomedical Applications

Contact Info

Product

Resources

About